Bertino et al. observed that higher Cav-1 levels in tumor-associated stroma were significantly correlated with improved partial response rates (P = 0.036) and overall survival (OS) (P = 0.008) in advanced NSCLC patients, who treated with nanoparticle albumin-bound (nab) paclitaxel plus with carboplatin [110]. Here, CAV1 is linked to non-small cell lung carcinoma.